Shaker Investments LLC OH Has $430,000 Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Shaker Investments LLC OH trimmed its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 42.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 58,085 shares of the biotechnology company’s stock after selling 42,627 shares during the period. Shaker Investments LLC OH’s holdings in Iovance Biotherapeutics were worth $430,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of IOVA. Brookstone Capital Management grew its holdings in shares of Iovance Biotherapeutics by 43.9% in the 3rd quarter. Brookstone Capital Management now owns 20,055 shares of the biotechnology company’s stock worth $188,000 after purchasing an additional 6,120 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Iovance Biotherapeutics by 11.6% during the third quarter. Exchange Traded Concepts LLC now owns 17,071 shares of the biotechnology company’s stock worth $160,000 after buying an additional 1,776 shares in the last quarter. ORG Wealth Partners LLC bought a new position in shares of Iovance Biotherapeutics in the third quarter valued at approximately $89,000. Creative Planning grew its position in Iovance Biotherapeutics by 2.6% during the 3rd quarter. Creative Planning now owns 73,489 shares of the biotechnology company’s stock worth $690,000 after acquiring an additional 1,896 shares during the last quarter. Finally, Vontobel Holding Ltd. increased its holdings in Iovance Biotherapeutics by 32.5% during the 3rd quarter. Vontobel Holding Ltd. now owns 18,940 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 4,647 shares in the last quarter. 77.03% of the stock is currently owned by institutional investors and hedge funds.

Iovance Biotherapeutics Trading Down 6.5 %

NASDAQ IOVA opened at $5.32 on Tuesday. Iovance Biotherapeutics, Inc. has a 12 month low of $5.30 and a 12 month high of $18.33. The stock has a 50-day simple moving average of $6.99 and a 200 day simple moving average of $8.89.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. UBS Group assumed coverage on Iovance Biotherapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $17.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a research report on Wednesday, November 6th. Finally, Piper Sandler decreased their price target on Iovance Biotherapeutics from $10.00 to $7.50 and set a “neutral” rating on the stock in a report on Friday, January 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $22.69.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.